ArticleFEBS open bio2025
Preparation and characterization of renal cell peptides from fetal rats for their antitumor activity.
Article in FEBS open bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Bioactive peptides with potent antitumor activity are attractive therapeutic agents. The present study aimed to prepare renal cell peptides (RCPs) from fetal rats to test their antitumor activities in vitro. Candidate peptides were characterized by capillary HPLC and MS and their bioactivity was predicted using PeptideRanker. The predicted top 10 bioactive peptides were synthesized and tested for their cytotoxicity against different types of tumor cells by cell counting kit-8 assays and their half maximal inhibitory concentration values were calculated. Protease-digested < 3 kDa protein products reduced the viability of Michigan Cancer Foundation (MCF)-7 cells in a dose-dependent manner. Functionally, many candidate peptides were predicted to have antitumor activity and the top ten peptides (RCPs 1-10) were synthesized. Interestingly, RCP1, 5 and 6 displayed preferable cytotoxicity against human cancer MCF-7, A549, HCT-116, Hela, HepG2 and SGC-7901 cells and their cytotoxicity was dose-dependent. RCPs prepared from fetal rats displayed potent cytotoxicity preferably against different types of cancer cells in vitro in a dose-dependent manner which may be valuable for the treatment of malignant tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.